1. Home
  2. POLE vs LUNG Comparison

POLE vs LUNG Comparison

Compare POLE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POLE
  • LUNG
  • Stock Information
  • Founded
  • POLE 2024
  • LUNG 1995
  • Country
  • POLE United States
  • LUNG United States
  • Employees
  • POLE N/A
  • LUNG N/A
  • Industry
  • POLE
  • LUNG Industrial Specialties
  • Sector
  • POLE
  • LUNG Health Care
  • Exchange
  • POLE NYSE
  • LUNG Nasdaq
  • Market Cap
  • POLE 296.0M
  • LUNG 299.3M
  • IPO Year
  • POLE 2024
  • LUNG 2020
  • Fundamental
  • Price
  • POLE $10.11
  • LUNG $7.52
  • Analyst Decision
  • POLE
  • LUNG Strong Buy
  • Analyst Count
  • POLE 0
  • LUNG 7
  • Target Price
  • POLE N/A
  • LUNG $12.64
  • AVG Volume (30 Days)
  • POLE 3.7K
  • LUNG 493.3K
  • Earning Date
  • POLE 01-01-0001
  • LUNG 04-30-2025
  • Dividend Yield
  • POLE N/A
  • LUNG N/A
  • EPS Growth
  • POLE N/A
  • LUNG N/A
  • EPS
  • POLE N/A
  • LUNG N/A
  • Revenue
  • POLE N/A
  • LUNG $83,789,000.00
  • Revenue This Year
  • POLE N/A
  • LUNG $17.96
  • Revenue Next Year
  • POLE N/A
  • LUNG $18.35
  • P/E Ratio
  • POLE N/A
  • LUNG N/A
  • Revenue Growth
  • POLE N/A
  • LUNG 22.01
  • 52 Week Low
  • POLE $9.94
  • LUNG $5.46
  • 52 Week High
  • POLE $11.16
  • LUNG $10.01
  • Technical
  • Relative Strength Index (RSI)
  • POLE N/A
  • LUNG 50.11
  • Support Level
  • POLE N/A
  • LUNG $6.97
  • Resistance Level
  • POLE N/A
  • LUNG $7.65
  • Average True Range (ATR)
  • POLE 0.00
  • LUNG 0.67
  • MACD
  • POLE 0.00
  • LUNG -0.18
  • Stochastic Oscillator
  • POLE 0.00
  • LUNG 23.40

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: